Zacks Rating on Idera Pharmaceuticals (IDRA)

Idera Pharmaceuticals (IDRA) : 3 analysts are covering Idera Pharmaceuticals (IDRA) and their average rating on the stock is 1, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Idera Pharmaceuticals (IDRA) : 2 Wall Street analysts covering Idera Pharmaceuticals (IDRA) believe that the average level the stock could reach for the short term is $5. The maximum price target given is $6 and the minimum target for short term is around $4, hence the standard deviation is calculated at $1.41.


Idera Pharmaceuticals, Inc. is up 21.88% in the last 3-month period. Year-to-Date the stock performance stands at -36.89%. Idera Pharmaceuticals (NASDAQ:IDRA): stock turned positive on Tuesday. Though the stock opened at $1.94, the bulls momentum made the stock top out at $1.95 level for the day. The stock recorded a low of $1.92 and closed the trading day at $1.95, in the green by 1.04%. The total traded volume for the day was 229,456. The stock had closed at $1.93 in the previous days trading.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company uses two drug discovery technology platforms to design and develop drug candidates. Using its Toll-like receptor (TLR) targeting technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its gene silencing oligonucleotide (GSO) technology, the Company is developing GSOs to turn off the messenger RNA (mRNA) associated with disease causing genes. The Companys drug candidates include IMO-8400 for Waldenstroms macroglobulinemia and diffuse large B-Cell lymphoma; IMO-2055/IMO-2125 for immune-oncology; IMO-8400 for dermatomyositis and Duchenne Muscular Dystrophy (DMD), and IMO-9200 for selected autoimmune disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.